Cells – Talk Bio

Lonza’s Vision for the Future: A Fireside Chat with New CEO Wolfgang Wienand

1 month ago talkbio0Tagged Biological Factors, CDMO, Cells, gene therapy, Industry, Leadership, Lonza, pharmaceutical manufacturing, Small Molecule, Wolfgang Wienand

Lonza, Wolfgang Wienand, CDMO, Pharmaceutical manufacturing, Biologics, Cell and gene therapy, Small molecules, Leadership transition, Industry outlook

Daiichi turns to Nosis for AI-designed RNA delivery tech

1 month ago talkbio0Tagged Biosciences, Cells, Chronic disease, Daiichi, Nosis, Partnership, RNA, Sankyo

Nosis, Daiichi, RNA, Sankyo, Partnership, Biosciences, Cells, Chronic disease

Rentschler Biopharma Exits Cell and Gene Therapy Sector, Refocuses on Biologics Manufacturing

3 months ago talkbio0Tagged Biological Factors, Biopharma, CDMO, Cells, Demand (clinical), gene therapy, Manufacturing, Market, Rentschler, Stevenage facility closure, strategic realignment

Rentschler Biopharma, strategic realignment, cell and gene therapy, biologics manufacturing, CDMO, market demand, Stevenage facility closure

WuXi AppTec Divests Cell and Gene Therapy Units to Altaris in Strategic Shift

4 months ago talkbio0Tagged Altaris ', AppTec, Cells, gene therapy, Pharmaceutical Outsourcing, Strategic Divestment, WuXi

WuXi AppTec, Cell and Gene Therapy, Altaris, Strategic Divestment, Biosecure Act, Pharmaceutical Outsourcing

Biopharmaceutical Manufacturing and Emerging Trends in 2024: A Global Outlook

4 months ago talkbio0Tagged 2024, Biopharmaceutical manufacturing, Biosimilars, Biotechnology, Cells, Drug Discovery, gene therapy, innovations, Precision Medicine, trends qualifier

Biopharmaceutical manufacturing, 2024 trends, personalized medicine, AI-driven drug discovery, biosimilars, cell and gene therapies, biotechnology innovations.

Optimizing Expression of Multi-chain and Bispecific Antibodies: Strategies and Considerations

7 months ago talkbio0Tagged Antibodies, Antibodies, Bispecific, Cells, Chinese Hamster Ovary, CHO, Cultured Cell Line, expression vector, Metabolic Engineering, Optimization, production, Recombinants, Stable status

Bispecific Antibodies (bsAbs), Recombinant Antibody Production, Chinese Hamster Ovary (CHO) Cells, Expression Vector Optimization, Metabolic Engineering, Stable Cell Line Development

Bionova Scientific Expands into Plasmid DNA Services for Cell and Gene Therapy Developers

11 months ago talkbio0Tagged Asahi Kasei, Biological Factors, Bionova, CDMO, Cells, DNA, Facility (object), gene therapy, Plasmids, Science, Texas

Bionova Scientific, Plasmid DNA, Cell and Gene Therapy, CDMO, Asahi Kasei Group, Biopharmaceuticals, Biologics, Texas Facility

Revolutionizing CAR-Ts: The Future of Automation and Decentralization in Cell and Gene Therapy Manufacturing

11 months ago11 months ago talkbio0Tagged Advanced therapies, Automation, CAR-Ts, Cells, Decentralization, Digital X-ray, gene therapy, Manufacture, Patient-Centered Care, Precision Medicine, Preventive monitoring, quality management systems, real-time, Regulatory Compliance, Supply chain logistics

Automation, Decentralization, CAR-Ts, Cell and gene therapy manufacturing, Advanced therapies, Personalized medicine, Regulatory compliance, Quality management systems, Supply chain logistics, Digital solutions, Real-time monitoring, Patient-centered care

CMS to Increase Reimbursement for New Sickle Cell Gene Therapies through Outcomes-Based Agreements

1 year ago talkbio0Tagged Administrative action, Burden, Casgevy, Cells, Centers for Medicaid and Medicare (CMS) Pnl, Central, CGT, Equitable Access, Fertility, Grail, Increased, Lyfgenia, Medicaid Access, Medicare & Medicaid Services, OBAs, Outcomes-Based Agreements, Reimbursement, sickle cell gene therapies

CMS (Centers for Medicare & Medicaid Services), Sickle Cell Gene Therapies, Increased Reimbursement, Outcomes-Based Agreements (OBAs), Cell and Gene Therapy (CGT) Access Model, Medicaid Access, Casgevy, Lyfgenia, Fertility Preservation Services, Equitable Access, Administrative Burden Reduction

Diagonal Therapeutics Secures $128 Million Series A Funding through Innovative Antibody Agonists

1 year ago talkbio0Tagged Antibody agonism, Cells, Diagonal, Funding, Rare Diseases, switches

Diagonal Therapeutics, Series A funding, Antibody agonism, Cellular “on” switches, Rare diseases